dc.creatorGalarce, Gloria D.
dc.creatorFoncea, Rocío
dc.creatorEdwards, Ana María
dc.creatorPessoa Mahana, Hernán
dc.creatorPessoa Mahana, Carlos David
dc.creatorEbensperger González, Roberto
dc.date.accessioned2010-01-22T13:32:34Z
dc.date.available2010-01-22T13:32:34Z
dc.date.created2010-01-22T13:32:34Z
dc.date.issued2008
dc.identifierBIOLOGICAL RESEARCH Volume: 41 Issue: 1 Pages: 43-50 Published: 2008
dc.identifier0716-9760
dc.identifierhttps://repositorio.uchile.cl/handle/2250/120861
dc.description.abstractThis study describes the effect of novel 6-Arylbenzimidazo[1,2-c]quinazoline derivatives as tumor necrosis factor alpha (TNF-alpha) production inhibitors. The newly synthesized compounds were tested for their in vitro ability to inhibit the lipolysaccharide (LPS) induced TNF-alpha secretion in the human promyelocytic cell line HL-60. The compound 6-Phenyl-benzimidazo[1,2-c]quinazoline, coded as G1, resulted as the most potent inhibitor and with no significant cytotoxic activity. Thus, 6-Arylbenzimidazo[1,2-c]quinazoline derivatives may have a potential as anti-inflammatory agents.
dc.languageen
dc.publisherSOC BIOLGIA CHILE
dc.subjectANTITUMOR
dc.titleBiological evaluation of novel 6-arylbenzimidazo [1,2-c]quinazoline derivatives as inhibitors of LPS-induced TNF-alpha secretion
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución